中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
21期
9638-9641
,共4页
康复新%氨基水杨酸类%结肠炎,溃疡性%干扰素Ⅱ型%白细胞介素4%白细胞介素12
康複新%氨基水楊痠類%結腸炎,潰瘍性%榦擾素Ⅱ型%白細胞介素4%白細胞介素12
강복신%안기수양산류%결장염,궤양성%간우소Ⅱ형%백세포개소4%백세포개소12
Kangfuxin%Aminosalicylic acids%Colitis,ulcerative%Interferon type II%Interleukin-4%Interleukin-12
目的:观察康复新、5-ASA及两者联合用药治疗大鼠溃疡性结肠炎(UC)的疗效。方法采用2,4,6-三硝基苯磺酸(2,4,6-TNBS)复制大鼠UC模型,并随机将其分为正常对照组、模型组、5-ASA治疗组、康复新治疗组以及联合治疗组,采用酶联免疫吸附法(ELISA)检测大鼠血清中IFN-γ、IL-4、IL-12的水平、采用免疫组织化学法检测大鼠结肠黏膜中IFN-γ、IL-4、IL-12的表达、实时荧光定量PCR(RT-PCR)检测结肠黏膜中IFN-γ、IL-4、IL-12 mRNA的表达。结果与模型组相比,康复新、5-ASA、联合治疗组大鼠血清中IL-12、IFN-γ的表达降低(P<0.01),IL-4的表达升高(P<0.01);与康复新组和5-ASA组相比,联合治疗组大鼠血清中IL-12和IFN-γ的水平表达明显下降(P<0.01),而IL-4的表达水平明显升高(P<0.01)。康复新组与5-ASA组比较无显著差异(P>0.05)。结论康复新可作为一种治疗大鼠UC的药物,且疗效与5-ASA相当,与5-ASA联合应用可达到最佳的治疗效果。
目的:觀察康複新、5-ASA及兩者聯閤用藥治療大鼠潰瘍性結腸炎(UC)的療效。方法採用2,4,6-三硝基苯磺痠(2,4,6-TNBS)複製大鼠UC模型,併隨機將其分為正常對照組、模型組、5-ASA治療組、康複新治療組以及聯閤治療組,採用酶聯免疫吸附法(ELISA)檢測大鼠血清中IFN-γ、IL-4、IL-12的水平、採用免疫組織化學法檢測大鼠結腸黏膜中IFN-γ、IL-4、IL-12的錶達、實時熒光定量PCR(RT-PCR)檢測結腸黏膜中IFN-γ、IL-4、IL-12 mRNA的錶達。結果與模型組相比,康複新、5-ASA、聯閤治療組大鼠血清中IL-12、IFN-γ的錶達降低(P<0.01),IL-4的錶達升高(P<0.01);與康複新組和5-ASA組相比,聯閤治療組大鼠血清中IL-12和IFN-γ的水平錶達明顯下降(P<0.01),而IL-4的錶達水平明顯升高(P<0.01)。康複新組與5-ASA組比較無顯著差異(P>0.05)。結論康複新可作為一種治療大鼠UC的藥物,且療效與5-ASA相噹,與5-ASA聯閤應用可達到最佳的治療效果。
목적:관찰강복신、5-ASA급량자연합용약치료대서궤양성결장염(UC)적료효。방법채용2,4,6-삼초기분광산(2,4,6-TNBS)복제대서UC모형,병수궤장기분위정상대조조、모형조、5-ASA치료조、강복신치료조이급연합치료조,채용매련면역흡부법(ELISA)검측대서혈청중IFN-γ、IL-4、IL-12적수평、채용면역조직화학법검측대서결장점막중IFN-γ、IL-4、IL-12적표체、실시형광정량PCR(RT-PCR)검측결장점막중IFN-γ、IL-4、IL-12 mRNA적표체。결과여모형조상비,강복신、5-ASA、연합치료조대서혈청중IL-12、IFN-γ적표체강저(P<0.01),IL-4적표체승고(P<0.01);여강복신조화5-ASA조상비,연합치료조대서혈청중IL-12화IFN-γ적수평표체명현하강(P<0.01),이IL-4적표체수평명현승고(P<0.01)。강복신조여5-ASA조비교무현저차이(P>0.05)。결론강복신가작위일충치료대서UC적약물,차료효여5-ASA상당,여5-ASA연합응용가체도최가적치료효과。
ObjectiveThe research is to observe the efficacy of Kangfuxin, 5-ASA respectively as well as that of the two combined in ulcerative colitis (UC) in rats.MethodsAfter the UC model being induced in the adult Waster rats through 2, 4, 6-trinitrobenzene sulfonic acid (TNBS), the rats are randomly divided into five groups: the normal group, the model group, the 5-ASA group, the Kangfuxin group and the combined group. Then enzyme-linked immunosorbent assay(ELISA) and immunohistochemistry are adopted to examine the level and expression of IFN-γ, IL-4, IL-12; Real-time PCR is used to determine their mRNA expressions.ResultsCompared with model group, IL-12 and IFN-γ expressions of the Kangfuxin, 5-ASA and combined groups decreased (P<0.01), while their IL-4 expression increased (P<0.01). Compared with the KangFuxin and 5-ASA groups, IL-12 and IFN-γ expression of the combined group decreased significantly (P<0.01), while its expression of IL-4 rose tremendously(P<0.01). The Kangfuxin group and the 5-ASA group showed no significant difference (P> 0.05).ConclusionAs an effective drug therapy for UC, Kangfuxin's efficacy is similar to 5-ASA. The combined therapy of the two seems to be superior to single-agent therapy.